Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Catalyst Pharmaceuticals (CPRX) Accumulated Depreciation & Amortization (2016 - 2026)

Catalyst Pharmaceuticals filings provide 16 years of Accumulated Depreciation & Amortization readings, the most recent being -$3000.0 for Q1 2026.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 98.41% to -$3000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$3000.0, a 98.41% increase, with the full-year FY2025 number at -$604000.0, down 98.68% from a year prior.
  • Accumulated Depreciation & Amortization hit -$3000.0 in Q1 2026 for Catalyst Pharmaceuticals, up from -$604000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $98000.0 in Q3 2022 to a low of -$1.2 million in Q2 2023.
  • Median Accumulated Depreciation & Amortization over the past 5 years was -$524000.0 (2024), compared with a mean of -$499823.5.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 110.89% in 2022 and later tumbled 868.37% in 2023.
  • Catalyst Pharmaceuticals' Accumulated Depreciation & Amortization stood at -$847000.0 in 2022, then surged by 75.91% to -$204000.0 in 2023, then tumbled by 49.02% to -$304000.0 in 2024, then plummeted by 98.68% to -$604000.0 in 2025, then skyrocketed by 99.5% to -$3000.0 in 2026.
  • The last three reported values for Accumulated Depreciation & Amortization were -$3000.0 (Q1 2026), -$604000.0 (Q4 2025), and -$1000.0 (Q3 2025) per Business Quant data.